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64544 | RSC Adv., 2016, 6, 64544–645d ﬂavone derivatives provide
signiﬁcant insight into the structural features
required for enhanced anti-proliferative activity†
Divyashree Ravishankar,a Kimberly A. Watson,b Francesca Greco*a
and Helen M. I. Osborn*a
With many cancers showing resistance to current chemotherapies, the search for novel anti-cancer agents
is attracting considerable attention. Natural ﬂavonoids have been identiﬁed as useful leads in such
programmes. However, since an in-depth understanding of the structural requirements for optimum
activity is generally lacking, further research is required before the full potential of ﬂavonoids as anti-
proliferative agents can be realised. Herein a broad library of 76 methoxy and hydroxy ﬂavones, and their
4-thio analogues, was constructed and their structure–activity relationships for anti-proliferative activity
against the breast cancer cell lines MCF-7 (ER +ve), MCF-7/DX (ER +ve, anthracycline resistant) and
MDA-MB-231 (ER ve) were probed. Within this library, 42 compounds were novel, and all compounds
were aﬀorded in good yields and >95% purity. The most promising lead compounds, speciﬁcally the
novel hydroxy 4-thioﬂavones 15f and 16f, were further evaluated for their anti-proliferative activities
against a broader range of cancer cell lines by the National Cancer Institute (NCI), USA and displayed
signiﬁcant growth inhibition proﬁles (e.g. compound-15f: MCF-7 (GI50 ¼ 0.18 mM), T-47D (GI50 ¼ 0.03
mM) and MDA-MB-468 (GI50 ¼ 0.47 mM) and compound-16f: MCF-7 (GI50 ¼ 1.46 mM), T-47D (GI50 ¼
1.27 mM) and MDA-MB-231 (GI50 ¼ 1.81 mM)). Overall, 15f and 16f exhibited 7–46 fold greater anti-
proliferative potency than the natural ﬂavone chrysin (2d). A systematic structure–activity relationship
study against the breast cancer cell lines highlighted that free hydroxyl groups and the B-ring phenyl
groups were essential for enhanced anti-proliferative activities. Substitution of the 4-C]O functionality
with a 4-C]S functionality, and incorporation of electron withdrawing groups at C-40 of the B-ring
phenyl, also enhanced activity. Molecular docking and mechanistic studies suggest that the anti-
proliferative eﬀects of ﬂavones 15f and 16f are mediated via ER-independent cleavage of PARP and
downregulation of GSK-3b for MCF-7 and MCF-7/DX cell lines. For the MDA-MB-231 cell line,
restoration of the wild-type p53 DNA binding activity of mutant p53 tumour suppressor gene was indicated.Introduction
Natural products and their derivatives provide a signicant
number of new chemical leads for drug discovery programmes
within a wide range of clinical areas.1 For example, analysis of
plant-based compounds has highlighted many potential clin-
ical applications for avonoids.2 Within the area of avonoidsing, Whiteknights, RG6 6AD, Reading,
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56as anticancer agents,3–11 the success of such approaches
has been exemplied through the development of avone
derivatives such as avopiridol (for chronic lymphocytic
leukemia),12–14 silibinin (for prostate cancer),15 and quercetin16
and its derivative QC12 17 (for ovarian cancer), which are at
various stages of clinical application. Although the natural
avonoids demonstrate anti-proliferative activities and can
themselves act as useful leads, these activities have oen been
reported at pharmacologically non-achievable high micromolar
concentrations (50–100 mM).18–21 Therefore, medicinal chem-
istry strategies are essential to optimise the pharmacokinetic
proles of these compounds, in order to ensure that the full
clinical applications for avonoids are realised. In this study, we
have proposed methylation of hydroxyls, and conversion of 4-
C]O to 4-C]S, as a promising strategy to improve the activities
of avonoids, since these structural motifs could lead to avo-
noids with desirable physiochemical properties such as
increased lipophilicity and metabolic stability. Therefore, theThis journal is © The Royal Society of Chemistry 2016
Scheme 2 Synthesis of 4-thiocarbonyl analogues of the hydroxy and
methoxy ﬂavones (1e–f to 19e–f) (i) dry toluene, Lawesson's reagent,
110 C, 4 h (ii) dry DCM, BBr3, room temperature/40 C, 4 h/overnight.
Paper RSC Advancesaim of this study was to elucidate the eﬀects of methylation of
free hydroxyls and 4-C]S substitution on the anti-proliferative
properties of the avonoids by undertaking the systematic
design, synthesis and biological analysis of a well-dened
library of hydroxy avone analogues. In addition, synthesis of
this library of compounds would allow structure–activity rela-
tionships (SARs) to be determined. This is of particular impor-
tance for avonoids as in-depth understanding of the SARs for
anticancer properties of avones is still limited.22,23 Specically,
the signicance of some of their core structural features for
activity, such as hydroxyl substitutions at diﬀerent positions on
the avonoid rings, and the eﬀect of methylation of the free
hydroxyls on activity, are poorly dened. Also, the impact of
modifying the 4-C]O substituent on the anticancer activities of
avones has not been extensively studied.Results and discussion
Design and synthesis
To realise the aims of this study, structurally related hydroxy
and methoxy avones, and their 4-thio derivatives, were syn-
thesised. The synthesis of the methoxy and hydroxy avone
scaﬀolds was achieved using a synthetic strategy involving
the Baker–Venkataraman rearrangement as a key step
(Scheme 1).24,25 The 4-thio analogues were obtained according to
Scheme 2 26 in 20–30% overall yield (see Experimental section in
ESI† material for full details).
First, the eﬀects of methylation and 4-thio modications on
avones with diﬀerent numbers of hydroxyl groups and
diﬀerent positions of hydroxyls on ring-A, were investigated.
Thus, 20 avones comprising of (i) dihydroxy avones with
hydroxyl substitution on ring-A at the C-7,8 or C-5,7 positions,
(ii) tetrahydroxy avones with dihydroxyl substitution on ring-A
(at the C-7,8 or C-5,7 positions) and on ring-B (at the C-30 and C-
40 positions), and (iii) pentahydroxy avones with dihydroxyl
substitution on ring-A (at the C-5,7 position only) and on ring-B
(at the C-30 and C-40 positions) as well as a hydroxyl group at theScheme 1 Synthesis of methoxy ﬂavones and hydroxy ﬂavones (1c–
d to 19c–d) (i) pyridine, 75 C, 1 h; (ii) pyridine, KOH, 50–75 C, 2 h; (iii)
(a) glacial acetic acid, 1% H2SO4, 90–110 C, 1 h, (b) CHCl3, 0 C to
room temperature, 30 min (iv) dry DCM, BBr3, room temperature/40
C, 4 h/overnight.
This journal is © The Royal Society of Chemistry 2016C-3 position on ring-C were designed and synthesised. The
analogous methoxy and 4-thio derivatives were also prepared
(compounds-1c–f to 5c–f, series-1, Fig. 1).
The pentahydroxy avone (quercetin) derivatives (5c–f) were
obtained starting from pentahydroxy avone (purchased)
according to Scheme 3 27,28 in 36% overall yield and with 99%
purity by HPLC. This represents an improvement on the
recently reported synthesis of 5f, both in terms of overall yield
and purity29 (22% overall yield and 95% purity). The panel of
avones studied herein also contained the well-known natural
avones chrysin (2d), luteolin (4d) and quercetin (5d) to allow
comparisons to be made between the novel analogues prepared
in our laboratory and some standard avonoids. The design of
further series of avones was guided by the anti-proliferative
activities of series-1 compounds. Therefore, compound-2f,
a dihydroxy 4-thio avone that was identied to possess
promising anti-proliferative activity in in vitro screening (dis-
cussed below), was considered as a candidate for further opti-
misation through the bioisostere approach and Topliss
scheme.30 This resulted in the synthesis of a focused set of
dihydroxy avone analogues (bearing C-7,8 and C-5,7 hydroxyls
on ring-A) with phenyl bioisosteres (series-2, Fig. 1), and phenyl
groups with electron-withdrawing substituents at the C-40
position (based on the Topliss scheme for the optimisation ofFig. 1 Library of the synthesised ﬂavone derivatives. Novel
compounds are highlighted in bold.
RSC Adv., 2016, 6, 64544–64556 | 64545
Scheme 3 Synthesis of methoxy and 4-thiocarbonyl analogues of
pentahydroxy ﬂavone (5c–f) (i) dimethyl sulfate, 15% KOH, room
temperature to 90 C, overnight (ii) dry toluene, Lawesson's reagent,
110 C, 4 h (iii) dry DCM, BBr3, 40 C, overnight.
RSC Advances Paperphenyl ring substitution in drug design30) (series-3, Fig. 1) as
ring-B. The series-2 bioisosteric analogues of 2f comprised of
dihydroxy and dimethoxy avones, as well as their 4-thioavone
derivatives, with a ve-membered 2-thienyl and 2-furanyl group,
and a six-membered 3-pyridyl group [compounds 6c–f to 11c–f].
Series-3 involved 7,8 and 5,7 dihydroxy, dimethoxy avones, and
their 4-thio avone analogues with electron-withdrawing
groups (EWGs) such as uoro (–F), chloro (–Cl), bromo (–Br)
and cyano (–CN) at the C-40 position of the phenyl ring (ring-B)
[compounds 12c–f to 19c–f]. It is noteworthy that for the
synthesis of novel avones containing nitrogen atoms (e.g. the
3-pyridyl and 4-cyano phenyl groups), during the cyclisation
step (step (iii-a)) in the presence of concentrated sulfuric acid in
glacial acetic acid, the 1,3-diketone intermediates (compound
10b, 11b and 19b) were found to undergo hydrolysis instead of
cyclisation and dehydration, to yield the corresponding
methoxy avones. Therefore, the cyclisation of such 1,3-dike-
tones was instead accomplished in high yields (70–80%) by the
addition of concentrated sulfuric acid into the solution of the
1,3-diketone in CHCl3 at 0 C31 (step (iii-b)).
Overall, multiple series of avone derivatives comprising of
hydroxy avones (free –OH and 4-C]O), hydroxy 4-thioavones
(free –OH and 4-C]S), methoxy avones (–OMe and 4-C]O)
andmethoxy 4-thioavones (–OMe and 4-C]S) with diﬀerent B-
ring substitutions were successfully synthesised (summarised
in Fig. 1). Out of 76 compounds, 42 compounds (3e, 3f, 4f, 6d–f,
7c–f, 8c–f, 9c, 9e, 9f, 10e, 10f, 11e, 11f, 12e, 12f, 13e, 13f, 14c–f,
15e, 15f, 16c–f, 17e, 17f, 18c, 18e, 18f, 19c, 19e and 19f) were
prepared and characterised for the rst time. All of the syn-
thesised compounds were characterised by 1H and 13C NMR
and IR spectroscopy, and high-resolution mass spectrometry.
The purity of these compounds was established by reverse
phase HPLC and the purities were found to be >95% in all cases.Anti-proliferative evaluation
As avonoids have been reported to show activity against breast
cancer cell lines,32–34 all of the synthesised compounds (1c–f to
19c–f) were evaluated for their anti-proliferative activity against
the estrogen-responsive breast cancer cell lines MCF-7, and the
clinically relevant anthracycline-resistant MCF-7/DX (which
mimics the multi-drug resistant scenario in patients), as well as
the estrogen-independent, triple negative breast cancer cell line
MDA-MB-231, using the MTT assay. The initial series of
compounds (series 1, i.e. 1c–f to 5c–f) was rst evaluated against
MCF-7 and MCF-7/DX cell lines to investigate the eﬀects of
methylation and 4-thio substitution on avones with diﬀering64546 | RSC Adv., 2016, 6, 64544–64556numbers of hydroxyl groups as well as with diﬀerent positions
on the A-ring. The IC50 values (half maximal inhibitory
concentration) of these compounds were determined as
a measure of their respective cytotoxicity and these values are
tabulated in Table 1. For this series, compound-2f with the
dihydroxy groups at the C-5,7 positions on ring-A, and 4-thio
substitution, showed the highest anti-proliferative potency with
IC50 values of 7.1 0.51 mM and 34.93 5.75 mM against MCF-7
and MCF-7/DX cell lines, respectively. Compounds 1f, 3e, 3f, 4d
and 5d showed moderate cytotoxicity with IC50 values of 25.6 
1.26 mM, 23.5  4.27 mM and 11.8  1.79 mM, respectively
however, these compounds were weakly anti-proliferative
against the MCF-7/DX cell line with IC50 values of 176.3 
1.61 mM, >250 mM and >250 mM, respectively. Compounds 1c,
1d, 1e, 9c, 3c, 3d, 4c, 4e, 5c, 5e and 5fwere found to be less active
against both MCF-7 and MCF-7/DX cell lines with IC50 values
>30 mM and >85 mM, respectively. The IC50 values for the well-
known natural avones in this series, 2d (chrysin), 4d (luteo-
lin) and 5d (quercetin) were found to be 25.6  1.26 mM, 21.6 
0.81 mMand 13.7 0.61 mM, respectively, against theMCF-7 cell
line and the obtained values are in the range of their literature
reported values.35,36 In general, all compounds exhibited a 3–10
fold lower anti-proliferative activity against MCF-7/DX, which
could be because these compounds might act as substrates of
the eﬄux pump P-gp, which is generally over expressed in the
MCF-7/DX cell line.37
Next, series 1 compounds (1c–f to 5c–f) were assessed for
their anti-proliferative activities at 10 mM concentration against
an ER ve hormone-independent breast cancer cell line, MDA-
MB-231. The 4-thio derivatives, and in particular the hydroxy
compounds, exhibited greater anti-proliferative activity than the
methoxy and hydroxy avone analogues. However, no deriva-
tives reached the IC50 at 10 mM (see ESI, Fig. S1†).
As compound-2f was identied as a promising lead
compound, further novel analogues of compound-2f were
prepared to discover more active avone derivatives. Thus
a series of bioisosteric analogues of the B-ring phenyl group of
compound-2f (series-2, compounds 6c–f to 11c–f), and a series
of compound-2f analogues with electron-withdrawing substit-
uents at the C40 position (series-3, compounds 12c–f to 19c–f),
along with their methoxy (both 4-C]O and 4-C]S) and their
7,8-regioisomeric analogues (both 4-C]O and 4-C]S), were
synthesised and evaluated for their anti-proliferative activities.
Since compound-2f was identied to be active below 10 mM and
50 mM against MCF-7 and MCF-7/DX, respectively, these
subsequently synthesised compounds were initially assessed for
their anti-proliferative activities at 10 mM concentration against
the MCF-7 and MDA-MB-231 cell lines, and at 50 mM against the
MCF-7/DX cell line. Compounds that reduced the cell viability
below 50% in the initial screening were arbitrarily classied as
‘active’ and they were then evaluated at a range of concentra-
tions (between 0.1 and 100 mM) against the respective cell line to
determine their IC50 values.
In the initial screening, series-2 compounds with bio-
isosteric replacements showed a decreased/complete loss of
activity with cell viability > 50% (see ESI, Fig. S2†). Among
series-3, the novel compounds 14f and 16f were found to beThis journal is © The Royal Society of Chemistry 2016
Table 1 IC50 values of the compounds from series 1 (1c–f to 5c–f) against the MCF-7 and MCF-7/DX cell lines
a
Chemical structure Compound Substitution IC50 in MCF-7 IC50 in MCF-7/DX
1c R1,2 ¼ OMe, X ¼ O 35.2  4.4 mM 77.0  4.2 mM
1d R1,2 ¼ OH, X ¼ O 38.0  0.6 mM 86.7  0.9 mM
1e R1,2 ¼ OMe, X ¼ S 34.7  1.7 mM 90.3  0.8 mM
1f R1,2 ¼ OH, X ¼ S 14.7  1.0 mM 47.2  1.2 mM
2c R1,2 ¼ OMe, X ¼ O 35.2  4.4 mM >250 mM
2d R1,2 ¼ OH, X ¼ O 25.6  1.2 mM 176.3  1.6 mM
2e R1,2 ¼ OMe, X ¼ S 23.5  4.2 mM >250 mM
2f R1,2 ¼ OH, X ¼ S 7.9  0.2 mM 34.9  5.7 mM
3c R1,2,3,4 ¼ OMe, X ¼ O >250 mM >250 mM
3d R1,2,3,4 ¼ OH, X ¼ O 97.5  6.7 mM 183.9  9.0 mM
3e R1,2,3,4 ¼ OMe, X ¼ S 11.8  1.7 mM >250 mM
3f R1,2,3,4 ¼ OH, X ¼ S 16.9  1.2 mM 66.8  0.7 mM
4c R1,2,3,4 ¼ OMe, X ¼ O >250 mM >250 mM
4d R1,2,3,4 ¼ OH, X ¼ O 21.6  0.8 mM 81.1  1.7 mM
4e R1,2,3,4 ¼ OMe, X ¼ S >250 mM >250 mM
4f R1,2,3,4 ¼ OH, X ¼ S 27.3  1.5 mM 75.9  3.0 mM
5c R1,2,3,4,5 ¼ OMe, X ¼ O 140.0  1.6 mM 245.1  2.5 mM
5d R1,2,3,4,5 ¼ OH, X ¼ O 13.7  0.6 mM 80.4  1.7 mM
5e R1,2,3,4,5 ¼ OMe, X ¼ S >250 mM >250 mM
5f R1,2,3,4,5 ¼ OH, X ¼ S 102.6  5.3 mM 139.3  6.8 mM
a Note: most active compound of the series is highlighted in bold.
Paper RSC Advancesactive against all three cell lines, and novel compounds 13f, 15f,
17f and 19f were found to be active against both the MCF-7 and
MCF-7/DX cell lines. Novel compounds 12f and 18f were found
to be active only against the MCF-7 cell line (Fig. 2). These active
compounds were further tested against the respective cell lines
at diﬀerent concentrations ranging from 0.1 to 100 mM to
determine their IC50 values. The determined IC50 values are
listed in Table 2. Among these, novel compounds 15f (IC50¼ 1.0
 0.1 mM and 9.1  0.1 mM against MCF-7 and MCF-7/DX cell
lines respectively) and 16f (IC50 ¼ 4.9  0.7 mM, 6.5  0.4 mM
and 8.9  0.9 mM against MCF-7, MCF-7/DX and MDA-MB-231
cell lines respectively) were identied as active compounds.
Novel insights into structure–activity relationships (SARs).
Comparison of the anti-proliferative activities of methoxy
avones (both 4-C]O and 4-C]S) with their corresponding
hydroxy avones illustrates that the methoxy avones were less
anti-proliferative than their hydroxy analogues with the excep-
tion of compound-3e [7,8,30,40-tetramethoxy 4-thioavone, IC50
¼ 11.8  1.79 mM against the MCF-7 cell line]. For example,
hydroxy avone 4d possesses an IC50 value of 21.6  0.8 mM,
whereas the IC50 value of its methoxy avone derivative-4c was
found to be >250 mM. This highlights that the free hydroxyls are
important for anti-proliferative activities (presumably via
hydrogen bonding interactions with the potential biological
cellular target).This journal is © The Royal Society of Chemistry 2016The importance of free hydroxyls for anti-proliferative
activity previously has been debated in the literature, with
contradicting results. Thus, the results from our programme
support ndings38,39 that indicate that polymethoxylation
decreases the anti-proliferative activity, but contradict earlier
ndings that suggested higher anti-proliferative activities for
polymethoxylated avones against MCF-7,20,40 human leukemic
HL-60 41 and melanoma cell lines.19
Further, from the comparison of anti-proliferative activities
between the hydroxy avones (free –OH and 4-C]O) and their
4-thio analogues (free –OH and 4-C]S), it was apparent that the
substitution of 4-C]S for 4-C]O enhances the anti-
proliferative activity [compound-2f (free –OH and 4-C]S), IC50
¼ 7.9  0.8 mM < compound-2d (free –OH and 4-C]O), IC50 ¼
25.6  1.2 mM].
(a) Inuence of number and position of hydroxyls. By
comparing the anti-proliferative activities of avone derivatives
(free –OH and 4-C]O) with diﬀerent numbers of hydroxy
groups, it was observed that the anti-proliferative activities
against the MCF-7 cell line were in the order pentahydroxy
avone (5d) [IC50 ¼ 13.7  0.6 mM] > tetrahydroxy avone (4d)
[IC50 ¼ 21.6  0.8 mM]z dihydroxy avone (2d) [IC50 ¼ 25.6 
0.6 mM]. However, an opposite correlation was observed in the
case of the hydroxy 4-thioavone derivatives (free –OH and 4-
C]S), where the order of anti-proliferative activities was foundRSC Adv., 2016, 6, 64544–64556 | 64547
Fig. 2 Anti-proliferative activities of compounds 12c–f to 19c–f
against (A) MCF-7 cell line (B) MCF-7/DX cell line (C) MDA-MB-231 cell
line. Cell viability was determined using MTT assay in the presence of
compounds 12c–f to 19c–f at 10 mM concentration against the MCF-7
cell line and MDA-MB-231 cell lines, and 50 mM concentration against
the MCF-7/DX cell line. Data are expressed as the mean  standard
error of the mean (SEM) (n ¼ 3). Cells without treatment serve as
control. Statistical signiﬁcance was estimated, with respect to the
control, by one-way ANOVA, followed by Bonferroni's post hoc test
(*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001). Dashed line
corresponds to 50% cell viability and those compounds showing <50%
cell viability were considered as active. Colour coding: blue – hydroxy
ﬂavone (–OH, 4-C]O), red – hydroxy 4-thioﬂavone (–OH, 4-C]S),
purple – methoxy ﬂavone (–OMe, 4-C]O) and green – methoxy 4-
thioﬂavone (–OMe, 4-C]S).
RSC Advances Paperto be dihydroxy 4-thioavone (2f) [IC50 ¼ 7.9  0.3 mM] > tet-
rahydroxy 4-thioavone (4f) [IC50 ¼ 27.3  1.5 mM] z penta-
hydroxy 4-thioavone (5f) [IC50 ¼ 102.6  5.4 mM]. This
indicates that the number of hydroxyls is not a determining
factor for the anti-proliferative activities, in the case of hydroxy
avones (free –OH and 4-C]O). In complete contrast, the
number of hydroxyl groups in hydroxy 4-thioavones plays an
important role in their anti-proliferative activities and the
dihydroxy 4-thioavones were found to be the most active
avones.
In terms of the position of the hydroxyls, avones with
5,7-hydroxyls on the A-ring were more active than their corre-
sponding 7,8-hydroxy avones. For example, 5,7,30,40-tetrahy-
droxy avone (4d) [IC50 ¼ 21.6  0.8 mM] > 7,8,30,40-tetrahydroxy
avone (3d) [IC50 ¼ 97.5  6.7 mM] and 5,7-dihydroxy 4-thio-
avone (2f) [IC50 ¼ 7.9  0.2 mM] > 7,8-dihydroxy 4-thioavone
(2e) [IC50 ¼ 14.7  1.0 mM].
(b) Eﬀect of bioisosteric replacements. Replacement of the B-
ring phenyl group with a bioisostere (e.g. either a ve-
membered 2-thienyl, a 2-furanyl group, or a six-membered 3-
pyridyl group) resulted in a signicant loss of anti-proliferative
activity. This highlighted that the presence of a phenyl group as
ring-B is favourable for anti-proliferative activity.64548 | RSC Adv., 2016, 6, 64544–64556(c) Inuence of electron-withdrawing groups. Interestingly,
introduction of EWGs at the C-40 position of the phenyl group,
mainly with halogens such as F (12f and 13f), Cl (14f and 15f)
and Br (16f and 17f) was found to enhance anti-proliferative
activities in comparison to the avones with an unsubstituted
phenyl B-ring (compounds 1f and 2f). In particular, the intro-
duction of Cl and Br groups increased the anti-proliferative
potencies 2–7 fold (14f, 15f, 16f and 17f) against MCF-7 and
MCF-7/DX cell lines, and also their introduction aﬀorded 7,8-
dihydroxy 4-thioavones with an increased anti-proliferative
activity towards MDA-MB-231 cells (compound-1f: cell viability
at 10 mMwas 79%, whereas, compound-14f (containing –Cl) and
compound-16f (containing –Br) showed 49% and 20% cell
viability at 10 mM against MDA-MB-231). The pronounced
activity observed for the –F, –Cl and –Br substituted 4-thio-
avones could be attributed to their increased lipophilicity, as
can be observed by the decrease in IC50 values (more active) for
increasing theoretical log P values (Table 2). A summary of SARs
for the anti-proliferative activities of avones analysed herein is
depicted in Fig. 3.
Molecular mechanism of action. Next, the probable molec-
ular mechanism of the anti-proliferative activities of the avo-
noids was explored. Two plausible molecular mechanisms were
postulated. (a) As the majority of avones evaluated herein
exhibited a strong and selective anti-proliferative activity
against the estrogen-responsive breast cancer cell line that
expresses high levels of estrogen receptor-a (ERa),42 it was
anticipated that these compounds may act as estrogen-receptor
antagonists by interacting with ERa. (b) As these compounds
have been reported to interact with cell signalling proteins4,43,44
it was hypothesised that these compounds could modulate the
cell signalling proteins that are involved in cell survival and cell
death.
(a) Interaction with ERa. The interaction of avones 1c–19f
with the estrogen receptor-a (ERa) was rst investigated using
a molecular docking approach. For this, compounds 1c–19f
were docked sequentially into the binding site of the prepared
X-ray crystallographic structure of human ERa complexed with
an antagonist 2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-
1,2,3,4-tetrahydro-isoquinolin-6-ol [native ligand] (PDB code
1UOM, 2.28 A˚ resolution)45 using a validated docking procedure
(see Experimental section). In general, no correlation was
observed between the order of anti-proliferative activity and
their binding aﬃnities with ERa (as determined by their
respective docking scores). One notable exception was
compound-3e which showed higher binding aﬃnity towards
the ERa receptor [(docking score of 10.02, versus the native
ligand docking score of 13.0), see ESI (Fig. S3†) for details]. This
suggests that the majority of the avonoid derivatives mediate
their anti-proliferative eﬀects via estrogen-independent mech-
anisms. A similar observation has been reported for 5-amino-
avones, which showed remarkable anti-proliferative activity
against the ER +ve MCF-7 cell line without ER competition, as
determined by the ER binding assay.46
To conrm this nding, an ERa antagonism assay was carried
out using the human estrogen receptor alpha assay kit whichThis journal is © The Royal Society of Chemistry 2016
Table 2 IC50 values of the compounds 12f to 19f against the MCF-7, MCF-7/DX andMDA-MB-231 cell lines and their correlation with theoretical
log P valuesa
Compound Chemical structure log P IC50 in MCF-7 IC50 in MCF-7/DX IC50 in MDA-MBA-231
18f 2.87 25.9  1.6 mM >50 mM >10 mM
12f 3.00 8.0  0.1 mM >50 mM >10 mM
14f 3.40 7.9  2.4 mM 34.0  4.6 mM 10.9  2.4 mM
16f 3.67 4.9  0.7 mM 6.50  0.4 mM 8.9  0.8 mM
19f 2.87 8.9  0.6 mM 27.3  1.8 mM >10 mM
13f 3.00 5.9  0.7 mM 41.3  1.5 mM >10 mM
15f 3.40 1.0  0.1 mM 9.1  0.8 mM >10 mM
17f 3.67 2.5  0.1 mM 15.4  0.8 mM >10 mM
a Note: most active compounds of the series are highlighted in bold. Data represented is mean  SEM, n ¼ 3. log P values were determined using
ChemDraw ultra 12.1 soware.
Paper RSC Advancesconsists of ERa reporter cells in which an ERa-responsive
promoter is functionally linked to the luciferase reporter gene,
and allows quantication of changes in the ERa activity viaFig. 3 Summary of the SARs for the anti-proliferative activities of
ﬂavones analysed herein.
This journal is © The Royal Society of Chemistry 2016measurement of the changes in luciferase expression. In order to
evaluate whether the avone derivatives mediate their anti-
proliferative eﬀects via antagonism of ERa, compound-15f
(IC50 ¼ 1 mM) compound-16f (IC50 ¼ 4.9 mM) and compound-3e
(IC50 ¼ 11.8  1.79 mM), that were potent against MCF-7 cells,
were assessed for their antagonist activity at four-point concen-
trations (10–0.1 mM) in the presence of a constant concentration
of 17b-estradiol (3.2 nM, EC75). The known antagonist fulvestrant
was used as a positive control. Compounds 15f and 16f did not
show any decrease in the luciferase activity (induced by 17b-
estradiol), which was in contrast to fulvestrant. However,
compound-3e showed a dose-dependent decrease in the lucif-
erase activity [see ESI (Fig. S4†) for details]. These results support
the ndings from the in silico study that the majority of theseRSC Adv., 2016, 6, 64544–64556 | 64549
Fig. 4 Chemiluminescent array images of the PathScan Intracellular
Signalling array kit revealing various phosphorylated/cleaved signalling
nodes in (A) MCF-7 cells, (B) MCF-7/DX cells and (C) MDA-MB-231
cells after the treatment with compounds 15f and 16f at 10 mM for 24 h.
Cells without treatment serve as control. Bar chart representing the
fold change in the integrated density of phosphorylated/cleaved sig-
nalling nodes in the array image of (A1) MCF-7 cells, (B1) MCF-7/DX
64550 | RSC Adv., 2016, 6, 64544–64556
RSC Advances Papercompounds (except compound-3e) most likely act through an
estrogen-independent mechanism.
(b) Interactions with cell signalling proteins. Next, the signals
mediated by compounds 15f and 16f in ER +ve MCF-7 and MCF-
7/DX cells and ER ve MDA-MB-231 cells were examined using
the PathScan® Intracellular Signalling Array Kit, which allows
simultaneous detection of 18 signicant and well-characterised
signalling molecules that undergo covalent post-translational
modications, such as phosphorylation and proteolysis
(cleavage). Protein samples obtained from the treatment of
MCF-7, MCF-7/DX and MDA-MB-231 cells with compounds 15f
(IC50 < 10 mM against MCF-7 and MCF-7/DX) and 16f (IC50 < 10
mM against MCF-7, MCF-7/DX and MDA-MB-231 cells) were
analysed (Fig. 4). The results showed that the anti-proliferative
eﬀects were mediated by signicant inhibition of the Akt asso-
ciated downstream target GSK-3b, which is a key signalling
molecule for cell survival and proliferation. In addition,
compound-15f, which showed greater potency towards MCF-7
cells (IC50 ¼ 1 mM for 15f vs. IC50 ¼ 4.9 mM for 16f), was
found to trigger cell death through PARP cleavage, which is
a hallmark of the cell death pathway.47 This explains the greater
potency of compound-15f towards MCF-7 cells. It is noteworthy
that no caspase-3 cleavage was observed; this suggests that the
observed PARP cleavage is caspase-3 independent and the
activation of PARP cleavage in MCF-7 cells might have been
executed via other caspases such as caspases-6/9.48 In the case of
MCF-7/DX cells, compound-16f, that has greater activity
towards MCF-7/DX cells than compound-15f, mediated its anti-
proliferative eﬀects through a signicant reduction in the
phosphorylation of several cell survival proteins such as mTOR,
GSK-3b and Stat3, along with induction of cell death through
caspase-3 and PARP cleavage. However, compound-15f was
found to elicit its anti-proliferative eﬀects through a reduction
in the phosphorylation of GSK-3b as well as through induction
of cell death via PARP cleavage. Thus, the higher potency of
compound-16f could be related to its ability to downregulate
multiple cell survival proteins (mTOR, GSK-3b and Stat3) along
with its ability to induce cell death via caspase-3 and PARP
cleavage.
Interestingly, treatment of MDA-MB-231 cells with
compound-16f showed a 2-fold increase in the levels of p53
compared to the control. MDA-MB-231 cells have a mutant p53
gene49,50 that is more stable and oncogenic unlike the wild type
p53 in MCF-7 cells.51 The presence of mutant p53 drives the
invasiveness of the tumour.52,53 However, the increase in the
serine-15 phosphorylated p53 (mutant) in compound-16f
treated MDA-MB-231 cells [than the control (untreated)] linked
with its profound activity suggest that compound-16f induces
Ser-15 phosphorylation of a mutant p53 in MDA-MB-231 cells,cells and (C1) MDA-MB-231 cells after the treatment with and without
compounds 15f and 16f at 10 mM for 24 h. Data are expressed as the
mean  standard error of the mean (SEM) (n ¼ 4). Statistical signiﬁ-
cance was estimated with respect to the control by one-way ANOVA,
followed by Bonferroni's post hoc test (*p < 0.05, **p < 0.01 and ***p <
0.001). (D) Molecular mechanism of action of 15f and 16f in MCF-7,
MCF-7/DX and MDA-MB-231 cell lines.
This journal is © The Royal Society of Chemistry 2016
Fig. 5 Apoptosis detection in MCF-7 and MDA-MB-231 cells by ﬂow
cytometry. MCF-7 cells were treated with compounds 15f and 16f at 1
mM and 5 mM respectively for 24 h andMDA-MB-231 cells were treated
with compounds 15f and 16f at 10 mM and 9 mM respectively for 24 h.
The quadrants were set based on the population of healthy, unstained
cells in untreated samples (control) compared to cells treated with 5
mM camptothecin for 24 h. (A) Representative ﬁgures showing pop-
ulation of unstained live (annexin V PI, lower left), apoptotic
(annexin V+ PI, lower right), dead (annexin V+ PI+, upper right) and
necrotic (annexin V PI+, upper left) cells. (B) Bar chart represent the
quantiﬁcation of the apoptotic cells induced upon the treatment of
MCF-7 and MDA-MB-231 cells with compounds 15f and 16f. Data are
expressed as mean  standard error of the mean (SEM), n ¼ 3.
Statistical signiﬁcance was estimated with respect to the control
(untreated sample) by one-way ANOVA, followed by Bonferroni's post
hoc test (ns¼ nonsigniﬁcant; *p < 0.05, **p < 0.01, ***p < 0.001, ****p
< 0.0001).
Table 3 GI50 values for 15f and 16f against 60 cell lines obtained from
NCI/DTP screeninga
Panel/cell line
GI50 (mM)
15f 16f
Leukaemia
CCRF-CEM 4.13 2.53
HL-60 2.99 1.66
K-562 3.39 2.47
MOLT-4 3.93 2.16
RPMI-8226 2.95 1.32
SR 3.97 2.54
Non-small cell lung cancer
A549/ATCC 9.20 3.26
EKVX 17.3 17.9
HOP-62 1.95 1.50
HOP-92 1.76 1.69
NCI-H226 14.6 7.22
NCI-H23 1.95 1.52
NCI-H322M 2.23 1.89
NCI-H460 3.09 0.97
NCI-H522 2.57 1.16
Colon cancer
COLO 205 16.8 10.7
HCC-2998 1.74 2.28
HCT-116 2.78 2.22
HCT-15 0.48 0.85
HT29 19.4 4.56
KM12 2.17 3.35
SW-620 3.85 2.60
CNS cancer
SF-268 3.57 2.18
SF-295 8.97 4.01
SF-539 3.48 1.98
SNB-19 3.85 2.95
SNB-75 2.91 4.55
U251 3.36 2.44
Melanoma
LOX IMVI 3.17 1.18
MALME-3M 1.81 1.87
M14 3.25 2.01
MDA-MB-435 3.46 2.98
SK-MEL-2 2.69 2.27
SK-MEL-28 4.67 2.94
SK-MEL-5 2.05 1.79
UACC-257 2.93 2.88
UACC-62 3.27 2.09
Ovarian cancer
IGROV1 1.14 2.56
OVCAR-3 1.96 1.23
OVCAR-4 0.57 2.03
OVCAR-5 12.1 5.83
OVCAR-8 3.34 2.28
NCI/ADR-RES 2.82 1.43
SK-OV-3 3.61 2.60
Renal cancer
786-0 7.35 2.89
A498 1.22 2.15
ACHN 2.53 2.35
Paper RSC Advanceswhich probably leads to the restoration of wild-type p53 DNA
binding activity and induction of cell death. A similar observa-
tion has been reported for resveratrol (a chalcone) wherein cell
death was induced by restoring the wild-type p53 DNA binding
activity via the phosphorylation of a mutant p53 at serine-15 in
prostate cancer DU145 cells.54–56 This might explain the higher
activity of compound-16f against MDA-MB-231 cells (IC50 ¼ 8.9
mM for 16f vs. IC50 > 10 mM for 15f).
Overall, these results correlate well with the in vitro ndings,
and suggest that for the MCF-7 and MCF-7/DX cell lines, the
anti-proliferative eﬀects are mediated via ER-independent
cleavage of PARP and downregulation of GSK-3b. For the
MDA-MB-231 cell line, activity could be due to restoration of the
wild-type p53 DNA binding activity of the mutant p53 tumour
suppressor gene.
Apoptosis determination. As compounds 15f and 16f were
found to act via induction of the apoptotic signalling pathway
(PARP, caspase-3 and p53), these compounds were further
assessed for their ability to induce apoptosis. For this, MCF-7
and MDA-MB-231 cells were treated (at their IC50 concentra-
tion for 24 h) with compounds 15f (1 mM and 10 mM against
MCF-7 and MDA-MB-231, respectively) or 16f (5 mM and 9 mM
against MCF-7 and MDA-MB-231, respectively) and wereThis journal is © The Royal Society of Chemistry 2016 RSC Adv., 2016, 6, 64544–64556 | 64551
Table 3 (Contd. )
Panel/cell line
GI50 (mM)
15f 16f
CAKI-1 3.12 2.65
RXF393 4.22 2.51
SN12C 2.83 2.61
TK-10 4.60 4.16
UO-31 1.28 1.02
Prostate cancer
PC-3 3.21 2.92
DU-145 4.26 2.67
Breast cancer
MCF-7 0.18 1.46
MDA-MB-231/ATCC 2.20 1.81
HS 578T 5.26 6.69
BT-549 3.40 2.19
T-47D 0.03 1.27
MDA-MB-468 0.47 2.08
a Note: sub-micromolar range GI50 values are highlighted in bold.
Fig. 6 Comparison of GI50 values of compounds 15f and 16f with 2d
(chrysin, a well-known natural ﬂavone). Data for 2d (chrysin) were
obtained from NCI/DTP screening: December 2010 (NSC407436).
RSC Advances Paperanalysed for phosphatidylserine externalization (apoptosis
marker)57,58 using an annexin V–FITC/propidium iodide (PI)
apoptosis detection assay and ow cytometry. As shown in
Fig. 5, a signicant increase in the percentage of apoptotic cells
in comparison to the untreated control was observed in the
MCF-7 cells treated with either 15f or 16f, and in the MDA-MB-
231 cells treated with 16f. These results clearly indicate that the
avones 15f and 16f potentially induce apoptosis in the MCF-7
and MDA-MB-231 cells, whilst only 16f potentially induces
apoptosis in MDA-MB-231 cells. These observations are in line
with the cytotoxicity data/protein array data. Therefore, from
the molecular mechanism of action studies, and the apoptotic
assay, for compounds 15f and 16f it can be concluded that these
compounds induce apoptotic cell death via PARP cleavage in
MCF-7 cells, and 16f triggers apoptosis by p53 induction in the
MDA-MB-231 cell line.
NCI 60 cell line screening. Finally, to further probe the
promising and signicant anti-proliferative activities of the
novel avonoids 15f and 16f, these compounds were screened
for in vitro cytotoxicity by the National Cancer Institute64552 | RSC Adv., 2016, 6, 64544–64556Developmental Therapeutic Program,59 USA (NCI/DTP, USA).
Initial evaluation was performed at a single dose of 10 mM
against 60 diﬀerent human tumour cell lines using the sulfo-
rhodamine B cytotoxic assay.60 Both compounds showed
potential growth inhibition against a wide range of cancer cell
lines (see ESI†). As a result, these compounds were selected for
further 5-dose assay screening against the 60 cell lines (0.01–100
mM). Three end points, specically the GI50 (concentration that
causes 50% growth inhibition), TGI (total growth inhibition)
and LC50 (the concentration of the drug at which the original
cell number is reduced by 50%) were determined. The mean
inhibitory doses (MID) against 60 cell lines for compound-15f
and compound-16f were 2.81 mM and 2.39 mM respectively. The
GI50 values determined for these two compounds against 60 cell
lines are presented in Table 3. Interestingly, both compounds
15f and 16f exhibited nanomolar range activity various cell
lines. Specically, compound-15f showed the highest cytotox-
icity against the breast cancer cell lines MCF-7 (GI50¼ 0.18 mM),
T-47D (GI50 ¼ 0.03 mM) and MDA-MB-468 (GI50 ¼ 0.47 mM),
HCT-15 (colon cancer, GI50 ¼ 0.48 mM), OVCAR-4 (ovarian, GI50
¼ 0.57 mM). Also, compound-16f, showed signicant cytotoxicity
against NCI-H460 (NSCLC, GI50 ¼ 0.97 mM) and HCT-15 (colon
cancer, GI50 ¼ 0.85 mM). The cytotoxicity prole of the well-
known avone chrysin (2d) [NSC407436] was retrieved from
the NCI database (mean dose graph provided in ESI†) for
comparison. Overall, compounds-15f and 16f were found to be
7–8 fold more potent than chrysin (MID-20.10 mM, against 51
cell lines). In particular, compounds-15f and 16f were found to
be 46 fold and 13 fold more active than chrysin against an
ovarian OVCAR-4 cell line, 43 fold and 24 fold more active than
chrysin against colon HCT-15 and 5 fold and 15 fold more active
than chrysin against the NSCLC NCI-H460 cell line, respectively
(Fig. 6).
Conclusions
A library of 76 compounds containing structurally related
methoxy and hydroxy avones, and their 4-thio analogues, has
been designed, synthesised and evaluated for anti-proliferative
activity against the breast cancer cell linesMCF-7 (ER +ve), MCF-
7/DX (ER +ve, anthracycline resistant) and MDA-MB-231 (ER
ve). Within this library, 42 compounds were prepared and
characterised for the rst time within our laboratory. The study
provided signicant insight into the structural features
required for enhancing the anti-proliferative proles of
avones, and identied two novel hydroxy 4-thioavones 15f
and 16f, as lead anti-proliferative agents (15f (IC50 ¼ 1.0  0.1
mM and 9  0.1 mM against MCF-7 and MCF-7/DX cell lines,
respectively) and 16f (IC50 ¼ 4.9  0.7 mM, 6.5  0.4 mM and 8.9
 0.8 mM against MCF-7, MCF-7/DX andMDA-MB-231 cell lines,
respectively)). A systematic SAR study highlighted the presence
of free hydroxyl groups, and the B-ring phenyl groups, as
essential for enhanced anti-proliferative activities. Replacement
of the 4-C]O functional group with the 4-C]S functional
group also enhanced the anti-proliferative activities. Incorpo-
ration of lipophilic electron withdrawing groups at C-40 of the B-
ring phenyl was found to be favourable, and the increasedThis journal is © The Royal Society of Chemistry 2016
Paper RSC Advanceslipophilicity correlates well with the greater anti-proliferative
activities. Molecular mechanistic studies have suggested that
the anti-proliferative eﬀects of avones 15f and 16f are medi-
ated via ER-independent cleavage of PARP and downregulation
of GSK-3b in the case of MCF-7 and MCF-7/DX cell lines. For the
MDA-MB-231 cell line, a probable restoration of the wild-type
p53 DNA binding activity of mutant p53 tumour suppressor
gene was indicated. Taken together, these results demonstrate
that the novel thioavones 15f and 16f oﬀer considerable
potential as anti-proliferative agents within medicinal chem-
istry programmes focussed on cancer. In addition, the SARs
derived herein are likely to contribute signicantly to the design
and synthesis of novel thioavones for further therapeutic
applications.
Experimental
Materials and methods
Cell line and culture. MCF-7 (ER +ve breast cancer cell line)
was provided by Tenovus Centre for Cancer Research (Cardiﬀ,
UK), MCF-7/DX (a doxorubicin resistant phenotype of MCF-7)
was obtained as a gi from Professor Luigi Quintieri from the
University of Padova, Italy and MDA-MB-231 (ER ve breast
cancer cell line) were purchased as a frozen stock from the
European Collection of Cell Cultures (ECACC). MCF-7 andMCF-
7/DX cells were cultured in RPMI 1640 supplemented with 5%
fetal bovine serum, MDA-MB-231 cells were cultured in DMEM
supplemented with 10% fetal bovine serum. All of the cell
culture reagents were obtained from Lonza, UK. The PathScan
Intracellular Signalling array kit was purchased from Cell
Signaling (Catalog number-7323). ERa receptor antagonist kit
was purchased from Indigo biosciences, USA. Annexin
V/propidium iodide apoptosis detection kit I was procured from
BD, Pharmingen™, UK. For the cell culture experiments, the
stock solutions of the test compounds (10 mg mL1) were
prepared in sterile DMSO and ethanol (1 : 1 v/v) and these
stocks were then appropriately diluted with the complete
culture medium and, the ethanol and DMSO levels were
maintained below 1% in the test concentrations. The IC50
values were calculated using MS excel 2010. Molecular docking
was performed using SYBYL-X-2.1 soware.
Synthesis. See the ESI.†
Anti-proliferative assay. Anti-proliferative activities of the
compounds were assessed using the MTT assay at 72 h of
treatment. For this, MCF-7 and MCF-7/DX cells were seeded at
a density of 4  104 cells per mL and MDA-MB-231 cells were
seeded at a density of 2  104 cells per mL into 96 well plates
and incubated for 24 h to allow attachment. Aer 24 h, the cells
were treated with these synthesised derivatives at a range of
concentrations (0 to 250 mM) or at single doses (10 mM against
MCF-7 and MDA-MB-231 cells, and 50 mM against MCF-7/DX
cells) for 67 h. Aer 67 h, MTT assay61 was carried out by the
addition of 20 mL of MTT (5 mg mL1) solution in PBS into each
well and the cells were incubated for 5 h. The purple crystals
formed were dissolved in 100 mL of DMSO and the plates were
read at 570 nm using a SPECTRA max UV spectrometer (Bio-
Rad). The data represented are the mean of the threeThis journal is © The Royal Society of Chemistry 2016individual experiments. The cell viability of the control is
considered to be 100%.
IC50 values presented here correspond to the concentration
(T/C)  100 ¼ 50, where T ¼ absorbance of the test well aer 72
h exposure to the test compound, C ¼ absorbance of control
well aer 72 h.
GI50 values presented here involve a correction for the cell
count at time zero. Therefore the GI50 value for a test drug
corresponds to the concentration [(T T0)/(C T0)] 100¼ 50,
where T ¼ absorbance of the test well aer 48 h exposure to the
test compound, C ¼ absorbance of control aer 48 h and T0 ¼
absorbance at time zero.Molecular docking
Docking validation. To validate the accuracy of the docking
procedure to be used, the original ligands were extracted from
the coordinate les (taken from the Protein Data Bank PDB),
and then docked again into the corresponding crystal structure
of the proteins, using the automated docking procedure in the
program Surex-Dock (SFXC),62,63 as provided by SYBYL-X-2.1.
The resulting ligand conformation from the docking proce-
dure was compared with the ligand conformation as found in
the actual crystal structure of the complex. Comparative struc-
tural orientation of the ligand was calculated as the root mean
square deviation (RSMD) between the docked ligand and the
ligand as found in the crystal structure, using the programme
LSQKAB, as provided in the CCP4 64 suite. If the root mean
square deviation (RMSD) value between the real and the best-
scored conformations is equal to or less than 2.0 A˚ (represent-
ing the grid spacing used for the docking procedure), then the
docking process was considered successful.65 In this case the
docking procedure was rst validated by re-docking the
extracted co-crystallised ligand of human estrogen receptor-
a (ERa) (2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-
tetrahydro-isoquinolin-6-ol) into the prepared target protein to
be used for docking. The RMSD between the docked confor-
mation, as generated by the docking algorithm and the native
co-crystallised ligand conformation was found to be 0.12 A˚,
which was well within the 2 A˚ grid spacing used in the docking
procedure, indicating that the docking method to be used was
reliable and valid. Furthermore, the interactions between the
docked ligand and the prepared target receptor mimicked those
observed in the crystal structure of the same.
Docking procedure. Docking studies were performed using
the programme Surex-Dock (SFXC)62 as provided by Sybyl-X
2.1. The X-ray crystallographic structures of human estrogen
receptor-a (ERa) complexed with an antagonist 2-phenyl-1-[4-(2-
piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydro-isoquinolin-6-ol
(PDB code-1UOM, 2.28 A˚ resolution)45 was retrieved from the
Protein Data Bank. The protein structure was prepared for
docking using the Biopolymer Structure Preparation Tool with
the implemented default settings provided in the SYBYL pro-
gramme suite. Hydrogens were added to the protein structures in
idealised geometries and an overall energy minimisation of each
protein was performed using the MMFF94 force eld, employing
a conjugate gradient algorithm66 with a convergence criterion ofRSC Adv., 2016, 6, 64544–64556 | 64553
RSC Advances Paper0.5 kcal mol1 A and up to 5000 iterations. Finally, before
the docking run, all watermolecules were removed and the ligand
2-phenyl-1-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-1,2,3,4-tetrahydro-
isoquinolin-6-ol was extracted from the coordinate le of the ERa
(PDB-1UOM). The protomol, representing the ligand binding
groove, was generated using a ligand directed method, which
allows the docking of ligands into predened sites, as dened by
occupancy of any co-crystallised ligand at the site of interest.
The Surex-X docking algorithm docks a given ligand to
a receptor using a exible ligand and a semi-exible receptor; in
this case the peptides were allowed to be fully exible while the
receptor was semi-exible. This approach allows for optimisa-
tion of potentially favourable molecular interactions, such as
those dened by hydrogen bond and van der Waal forces. The
docking results yield a docking score, which takes into
consideration entropic, polar, hydrophobic, repulsive and des-
olvation factors. Here, the docking scores were expressed in
log10 (Kd) units to represent binding aﬃnities, where Kd is the
dissociation constant. The free energy of binding of the ligand
to the protein was extrapolated from eqn (1).
Free energy of binding ¼ RT loge Kd (1)
The docking results were visualised using the programme
PyMOL67,68 and the molecular interactions of the docked
ligands were analysed by the programme CONTACTS, as
provided in the CCP4 suite of programmes.64,69,70 Potential
hydrogen bonds were assigned if the distance between two
electronegative atoms was less than 3.3 A˚, whereas any sepa-
ration greater than 3.3 A˚, but less than 4.5 A˚, was considered
a van der Waal interaction.
ERa antagonist assay. ERa reporter cells consisting of an
ERa-responsive promoter gene functionally linked to the
luciferase gene were defrosted and seeded into a 96-well plate
and these cells were immediately dosed with the test
compounds at diﬀerent concentrations (10–0.1 mM) and with
17b estradiol (3.2 nM, EC75 concentration) according to the
manufacturer's protocol. Aer 24 h incubation in the pres-
ence of the test compound or solvent (DMSO), the cell viability
of these treated/untreated reporter cells was measured to
eliminate false positives using the uorescence-based live cell
multiplex (LCM) assay. The uorescence from the live cells
was measured using the plate reader with the lter combi-
nation of [485 nm ex|535 nm em]. Following this, fold
reduction in the luciferase intensity, which is the measure of
the antagonist activity was measured by using a luminometer
(TECAN) according to the manufacturer's protocol. The data
are expressed as the fold reduction as compared to the
control. The mean of three experiments and the standard
error is reported.
PathScan sandwich immunoassay. The PathScan Intracel-
lular Signalling array kit was used for the simultaneous detec-
tion of 18 signicant and well-characterised cellular proteins
and signalling nodes that were phosphorylated or cleaved at the
specic residues.
(a) Preparation of cell lysate.MCF-7 andMCF-7/DX cells (8
104 cell per mL) and MDA-MB-231 cells (4  104 cells per mL)64554 | RSC Adv., 2016, 6, 64544–64556were seeded into 24 well plates (2 mL per well) and incubated
for 24 h. Aer 24 h, the cells were treated with the test
compounds at 10 mM concentration for 24 h. Following this 24 h
exposure, the cells were washed with ice-cold 1 phosphate-
buﬀered saline and lysed in 1 cell lysis buﬀer provided
(phosphotase and protease inhibitors added). These lysates
were quantied using the BCA protein assay.
(b) Assay procedure. The array blocking buﬀer was added to
each well of the glass slide provided and incubated for 15 min
at room temperature. Subsequently, the cell lysate, diluted to
0.3 mg mL1 in array diluents, was added to each well and
incubated for 2 h at room temperature. Subsequent to
washing, the detection antibody cocktail was added to each
well and incubated for 1 h at room temperature. Horseradish
peroxidase (HRP)-linked streptavidin was added to each well
and incubated for 30 min at room temperature. The slide was
then covered with LumiGLO/peroxide reagent (Cell Signaling
Technology) and exposed to lm for 2–30 s. The image was
captured by a digital imaging system, ImageQuant LAS 4000
(GE Healthcare).
Apoptosis detection assay. Apoptosis inMCF-7 andMDA-MB-
231 cells was assayed by annexin V and propidium iodide (PI) co-
staining using an Annexin-V–FITC staining kit according to the
manufacturer's instruction. 1  106 MCF-7 and MDA-MB-231
cells were plated into a 6 well plate (3.4  105 cells per mL, 3
mL per well). Aer 24 h incubation, cells were treated without
and with test compounds (at their IC50 concentration) for 24 h.
Cells were harvested using Accutase™ cell detachment solution
(1 mL per well) for 5 min at 37 C. Accutase was inactivated by
addition of complete medium (2 mL). Cells were collected by
centrifugation at 100  g and the pellet was washed twice with
cold PBS and then resuspended in 1 mL of annexin-binding
buﬀer. 100 mL of the cell suspension was transferred to 1.5 mL
Eppendorf tube and 5 mL of FITC-conjugated annexin V and 5 mL
of PI was added and incubated in dark for 15 min at room
temperature. Aer 15 min incubation 400 mL of annexin binding
buﬀer was added to the cells and the uorescence wasmeasured
using BD accuri™ instrument ow cytometry. The instrument
was set for FL1 (annexin V–FITC) vs. FL3 (PI) bivariant analysis.
Data from 10 000 cells per sample was collected and dot plots of
FL1 vs. FL3 were generated. The quadrants were set based on the
population of healthy, unstained cells in untreated samples
compared to cells treated with a known apoptotic inducer
camptothecin (5 mM) for 24 h. BD CSampler™ soware was used
to calculate the percentage of the cells in the respective quad-
rants. The experiment was performed in triplicate.
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